Daré Bioscience (DARE) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
11 Jun, 2026Opening remarks and agenda
Meeting commenced at 9:00 A.M. Pacific Time with introductions of directors, executive officers, and the independent auditor representative.
Chairperson outlined meeting procedures, including voting and Q&A protocols.
Shareholder proposals
Eight proposals were presented, including director elections, auditor ratification, executive compensation, voting frequency, equity issuance, stock plan amendment, and potential adjournments.
Overview of voting outcomes
Gregory Matz and Sabrina Martucci Johnson elected as Class III directors.
Haskell & White LLP ratified as independent auditor for fiscal year 2026.
Executive compensation approved on an advisory basis; annual frequency preferred for future votes.
Approval granted for potential future share issuance to Lincoln Park and amendment to increase shares in the 2022 Stock Incentive Plan by 1,500,000.
Adjournment proposals for additional proxy solicitation, if needed, were approved.
Latest events from Daré Bioscience
- Imminent launches and clinical milestones position the pipeline for strong near-term growth.DARE
TD Cowen 46th Annual Health Care Conference15 Jun 2026 - Okapi Partners LLC engaged for proxy solicitation ahead of the 2026 annual meeting.DARE
Proxy filing1 Jun 2026 - Annual meeting on June 11, 2026, with virtual voting and emphasis on shareholder participation.DARE
Proxy filing1 Jun 2026 - First product revenue expected June 2026, but ongoing viability depends on new capital.DARE
Q1 202620 May 2026 - Annual meeting covers director elections, compensation, auditor, and share issuance proposals.DARE
Proxy filing28 Apr 2026 - Shareholders will vote on director elections, auditor ratification, compensation, and key capital proposals.DARE
Proxy filing28 Apr 2026 - Proxy covers director elections, auditor ratification, compensation, and key capital structure proposals.DARE
Proxy filing17 Apr 2026 - DARE to PLAY launched nationwide; new product revenues and pipeline milestones expected in 2026-2027.DARE
Q4 202527 Mar 2026 - Q2 net income hit $12.9M on royalty sale, but liquidity and future losses remain concerns.DARE
Q2 20241 Feb 2026